Who
Steven Pieper
Officer
Company insider
Files Form 4 as: Chief Financial Officer, Xeris Biopharma Holdings; Chief Financial Officer, Xeris Pharmaceuticals.
In numbers
- Trades disclosed
- 66
- Buys
- 2
- Sells
- 5
- Bought
- $105K
- Sold
- $983K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 28 Jul 2021
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $47K5,000 at $9.41 | filing |
| 1 Sep 2026filed 1 Sep 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $43K5,000 at $8.50 | filing |
| 1 Sep 2026filed 1 Sep 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $43K5,000 at $8.50 | filing |
| 12 Aug 2026filed 12 Aug 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $43K5,000 at $8.50 | filing |
| 12 Aug 2026filed 12 Aug 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $43K5,000 at $8.50 | filing |
| 7 Jul 2026filed 7 Jul 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $235K27,600 at $8.52 | filing |
| 7 Jul 2026filed 7 Jul 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $235K27,600 at $8.52 | filing |
| 6 Jul 2026filed 7 Jul 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $148K17,400 at $8.50 | filing |
| 6 Jul 2026filed 7 Jul 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $148K17,400 at $8.50 | filing |
| 5 Mar 2026filed 5 Mar 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code M | $114K27,891 at $4.09 | filing |
| 5 Mar 2026filed 5 Mar 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code M | $83K14,036 at $5.93 | filing |
| 5 Mar 2026filed 5 Mar 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,891 at $0.00 | filing |
| 5 Mar 2026filed 5 Mar 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,891 at $0.00 | filing |
| 5 Mar 2026filed 5 Mar 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,036 at $0.00 | filing |
| 5 Mar 2026filed 5 Mar 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,036 at $0.00 | filing |
| 5 Mar 2026filed 5 Mar 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code M | $114K27,891 at $4.09 | filing |
| 5 Mar 2026filed 5 Mar 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code M | $83K14,036 at $5.93 | filing |
| 31 Jan 2026filed 2 Feb 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code F | $823K111,765 at $7.36 | filing |
| 31 Jan 2026filed 2 Feb 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code F | $489K66,450 at $7.36 | filing |
| 31 Jan 2026filed 2 Feb 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code F | $201K27,319 at $7.36 | filing |
News
Reviewing MediciNova (NASDAQ:MNOV) & Xeris Biopharma (NASDAQ:XERS)XERS · dailypolitical.com · 22 Oct 2026Critical Contrast: Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS)XERS · tickerreport.com · 21 Oct 2026Head-To-Head Survey: Organon & Co. (NYSE:OGN) versus Xeris Biopharma (NASDAQ:XERS)XERS · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name Steven Pieper; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.